van Zweeden AA, et al. - Folic acid and vitamin B12 supplementation resulted in reduced toxicity and enhanced efficacy of cisplatin in preclinical research and preceding clinical observations. Researchers, therefore, conducted this randomized phase 2 trial to assess the addition of folic acid and vitamin B12 to first-line palliative cisplatin and gemcitabine in patients with advanced esophagogastric cancer (AEGC). They found no improvement in the response rate, PFS, or overall survival in patients with AEGC taking cisplatin and gemcitabine following supplementation with folic acid and vitamin B12. The supplemented group had lower plasma homocysteine levels.